Genmab CEO: Tivdak launch has provided important experience for future treatments

The launch of Tivdak in the US, which is currently taking place, is providing Genmab with important experiences ahead of the launch of epcoritamab with partner Abbvie later this year, says company CEO Jan van de Winkel.
Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH
Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH
by andreas lønstrup, translated by catherine brett

Tivdak, which was approved as a cervical cancer treatment in the US last year, is the first drug that Danish biotech company Genmab has chosen to sell and market itself.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading